MPLT
MapLight Therapeutics, Inc.
Healthcare · Biotechnology · NMS
$29.55
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$1.3B
Trailing P/E
Forward P/E
-6.60
Rev Growth
Profit Margin
0.0%
ROE
-81.0%
Analyst Target
$35.00
Recommendation
STRONG BUY
About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow0.0
Moat40.0
Balance Sheet47.9
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: WATCH · Score: 36.7 · Rank: #4642
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$1.0B
Price/Book
2.86
Analysts
9
Total Debt
$5.6M
Rec. Mean
1.18
Short Ratio
4.56
Short % Float
0.1%
Employees
133

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 10 analysts at Strong Buy.
Price: $29.55 | Target: $37.90 (+28%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+28%
The Fundamentals
Profit Margin0.0%
ROE-81.0%
Forward P/E-6.6
Market Cap$1.3B
Position Sizing Scenarios
Stop: $25.12 (-15%) | Entry: $29.55
SharesCostProfit to TargetR:R
To Consensus ($37.90, 10 analysts)
10$295.50+$83.50 (28%)1.9R
50$1,477.50+$417.50 (28%)1.9R
100$2,955.00+$835.00 (28%)1.9R
Risk Factors
  • Elevated short interest (4.56 days to cover)
The Verdict
MapLight Therapeutics, Inc. holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
69.8
Risk Grade
Layers
7
Quality: HIGH_SORTINO,LOW_LIQUIDITY
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-7.8%
worst expected daily loss, 19 in 20 days
CVaR 95%
-8.8%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
1.94
above 1.0 is good
Max Drawdown
-30.3%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
30
Liquidity Grade
LOW
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
NONE
Bollinger Position
UPPER_HALF
Beta
Relative Volume
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
CAPR0.426
IMNM0.378
VKTX0.358
BEEM0.358
AAMI0.349
Inverse Correlated
TickerCorrelation
FORA-0.227
HCXY-0.222
1876.HK-0.221
0012.HK-0.215
9532.T-0.215
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Thursday
Worst Day
Friday
Best Month
Apr
Worst Month
Nov
Fri-Mon Effect
-0.7384024970783263
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-1.8%
3M Return
+71.0%
6M Return
+129.1%
12M Return
Momentum Rank
#275
Momentum Signal
STRONG_UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access